{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:34:05Z","timestamp":1785148445313,"version":"3.55.0"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.virol.2024.110026","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T11:19:45Z","timestamp":1707995985000},"page":"110026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Mucosal vaccines for viral diseases: Status and prospects"],"prefix":"10.1016","volume":"593","author":[{"given":"Bingjie","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxiao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanfang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haigang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peirong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2024.110026_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41590-019-0568-x","article-title":"Influenza-induced monocyte-derived alveolar macrophages confer prolonged antibacterial protection","volume":"21","author":"Aegerter","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi5246","article-title":"Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine","volume":"7","author":"An","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.virol.2024.110026_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110026_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejpb.2017.11.001","article-title":"Intranasal immunization with dry powder vaccines","volume":"122","author":"Bahamondez-Canas","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.virol.2024.110026_bib5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination: past, present and future","volume":"10","author":"Bandyopadhyay","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.virol.2024.110026_bib6","series-title":"Efficacy of Parainfluenza Virus 5 (PIV5)-Vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 Variants","author":"Beavis","year":"2022"},{"key":"10.1016\/j.virol.2024.110026_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5482087","article-title":"Mucosal vaccine development based on liposome technology","volume":"2016","author":"Bernasconi","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.virol.2024.110026_bib8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/nri2436","article-title":"Viral evasion and subversion of pattern-recognition receptor signalling","volume":"8","author":"Bowie","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib9","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/0264-410X(94)90143-0","article-title":"Towards rabies elimination in Belgium by fox vaccination using a vaccinia-rabies glycoprotein recombinant virus","volume":"12","author":"Brochier","year":"1994","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.virol.2024.110026_bib10","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1093\/infdis\/jiu295","article-title":"Vaccine-derived polioviruses","volume":"210","author":"Burns","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110026_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.12.040","article-title":"Influence of particle size on regional lung deposition--what evidence is there?","volume":"406","author":"Carvalho","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.virol.2024.110026_bib12","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110026_bib13","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.scib.2022.05.018","article-title":"A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2","volume":"67","author":"Chen","year":"2022","journal-title":"Sci. Bull."},{"key":"10.1016\/j.virol.2024.110026_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1021\/mp200392g","article-title":"A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and Guinea pigs","volume":"9","author":"Choi","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.virol.2024.110026_bib15","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1016\/j.vaccine.2006.12.054","article-title":"The safety and efficacy of the oral rabies vaccine SAG2 in Indian stray dogs","volume":"25","author":"Cliquet","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2024.110026_bib16","volume":"vol. 8","author":"Collins","year":"2020"},{"key":"10.1016\/j.virol.2024.110026_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41385-021-00428-0","article-title":"Mucosal immunity to poliovirus","volume":"15","author":"Connor","year":"2022","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib18","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110026_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/science.abj0299","article-title":"Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"373","author":"Corbett","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.virol.2024.110026_bib20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/imm.13526","article-title":"Vaccines, adjuvants and key factors for mucosal immune response","volume":"167","author":"Correa","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.virol.2024.110026_bib21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fimmu.2013.00185","article-title":"Multi-faceted functions of secretory IgA at mucosal surfaces","volume":"4","author":"Corth\u00e9sy","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3389\/fimmu.2018.00431","article-title":"Lipid-based particles: versatile delivery systems for mucosal vaccination against infection","volume":"9","author":"Corth\u00e9sy","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/mi.2010.55","article-title":"Topical immunization strategies","volume":"3","author":"Czerkinsky","year":"2010","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib24","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1126\/science.aax4040","article-title":"PIRs mediate innate myeloid cell memory to nonself MHC molecules","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2024.110026_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009928","article-title":"Induction of trained immunity by influenza vaccination - impact on COVID-19","volume":"17","author":"Debisarun","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2024.110026_bib26","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/s41467-023-37697-1","article-title":"An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters","volume":"14","author":"Deng","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2024.110026_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2024.110026_bib28","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1038\/s41467-020-18058-8","article-title":"A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction","volume":"11","author":"Ejemel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2024.110026_bib29","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41467-020-15575-4","article-title":"Structural morphing in a symmetry-mismatched viral vertex","volume":"11","author":"Fang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2024.110026_bib30","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.4155\/tde.11.68","article-title":"Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems","volume":"2","author":"Foged","year":"2011","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.virol.2024.110026_bib31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.virol.2024.110026_bib32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejps.2014.05.028","article-title":"Development of novel carrier(s) mediated tuberculosis vaccine: more than a tour de force","volume":"62","author":"Garg","year":"2014","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.virol.2024.110026_bib33","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1080\/21645515.2021.1920272","article-title":"Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines","volume":"17","author":"Gaspar","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2024.110026_bib34","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/milmed\/160.6.300","article-title":"Adenovirus vaccines in the U.S. military","volume":"160","author":"Gaydos","year":"1995","journal-title":"Mil. Med."},{"key":"10.1016\/j.virol.2024.110026_bib35","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMp2211314","article-title":"A covid-19 milestone attained - a correlate of protection for vaccines","volume":"387","author":"Gilbert","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110026_bib36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0140-6736(06)68815-6","article-title":"Rotavirus vaccines: current prospects and future challenges","volume":"368","author":"Glass","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2024.110026_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-00221-3","article-title":"Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19","volume":"5","author":"Graham","year":"2020","journal-title":"NPJ vaccines"},{"key":"10.1016\/j.virol.2024.110026_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7005a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2021-22 influenza season","volume":"70","author":"Grohskopf","year":"2021","journal-title":"MMWR Recomm. Rep. (Morb. Mortal. Wkly. Rep.)"},{"key":"10.1016\/j.virol.2024.110026_bib39","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1128\/CDLI.5.5.732-736.1998","article-title":"Effects of the nature of adjuvant and site of parenteral immunization on the serum and mucosal immune responses induced by a nasal boost with a vaccine alone","volume":"5","author":"Guy","year":"1998","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","volume":"399","author":"Halperin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2024.110026_bib41","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S1473-3099(22)00506-0","article-title":"Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Hardt","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2024.110026_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A single-dose intranasal Chad vaccine protects upper and lower respiratory tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2024.110026_bib43","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.virol.2024.110026_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114601","article-title":"Protein-coated nanoparticles are internalized by the epithelial cells of the female reproductive tract and induce systemic and mucosal immune responses","volume":"9","author":"Howe","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2024.110026_bib45","first-page":"56","article-title":"Polio eradication-lessons from the past and future perspective","volume":"8","author":"Jain","year":"2014","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.virol.2024.110026_bib46","first-page":"279","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Jenkin","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.virol.2024.110026_bib47","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41590-022-01354-4","article-title":"Parenteral BCG vaccine induces lung-resident memory macrophages and trained immunity via the gut-lung axis","volume":"23","author":"Jeyanathan","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2022.2155251","article-title":"Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial","volume":"12","author":"Jin","year":"2023","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.virol.2024.110026_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","article-title":"Vaccine technologies: from whole organisms to rationally designed protein assemblies","volume":"120","author":"Karch","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.virol.2024.110026_bib50","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2024.110026_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7774\/cevr.2017.6.1.15","article-title":"The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants","volume":"6","author":"Kim","year":"2017","journal-title":"Clinical and experimental vaccine research"},{"key":"10.1016\/j.virol.2024.110026_bib52","volume":"vol. 9","author":"King","year":"2021"},{"key":"10.1016\/j.virol.2024.110026_bib53","doi-asserted-by":"crossref","first-page":"7328","DOI":"10.1016\/j.vaccine.2017.03.076","article-title":"The rotavirus vaccine development pipeline","volume":"37","author":"Kirkwood","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2024.110026_bib54","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2183\/pjab.91.423","article-title":"The mucosal immune system: from dentistry to vaccine development","volume":"91","author":"Kiyono","year":"2015","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.virol.2024.110026_bib55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41541-023-00654-6","article-title":"Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report","volume":"8","author":"Knisely","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.virol.2024.110026_bib56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ni.3052","article-title":"The development and function of lung-resident macrophages and dendritic cells","volume":"16","author":"Kopf","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib57","first-page":"2963","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine","volume":"vol. 31","author":"Kuschner","year":"2013"},{"key":"10.1016\/j.virol.2024.110026_bib58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0264-410X(94)90095-7","article-title":"Vaccination against rabies: construction and characterization of SAG2, a double avirulent derivative of SADBern","volume":"12","author":"Lafay","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2024.110026_bib59","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s42003-021-02443-0","article-title":"ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models","volume":"4","author":"Lambe","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.virol.2024.110026_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn6868","article-title":"Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model","volume":"14","author":"Langel","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.virol.2024.110026_bib61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nbt.1635","article-title":"Rationalizing the development of live attenuated virus vaccines","volume":"28","author":"Lauring","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.virol.2024.110026_bib62","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.coi.2011.03.009","article-title":"Defending the mucosa: adjuvant and carrier formulations for mucosal immunity","volume":"23","author":"Lawson","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib63","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/S1473-3099(22)00502-3","article-title":"Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial","volume":"22","author":"Lazarus","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2024.110026_bib64","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41392-020-00434-x","article-title":"Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2","volume":"5","author":"Lei","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.virol.2024.110026_bib65","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clinre.2014.10.008","article-title":"The interplay between the intestinal microbiota and the immune system","volume":"39","author":"Lei","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.virol.2024.110026_bib66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nm0103-99","article-title":"Can needle-free administration of vaccines become the norm in global immunization?","volume":"9","author":"Levine","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.virol.2024.110026_bib67","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-021-01677-z","article-title":"Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial","volume":"28","author":"Li","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.virol.2024.110026_bib68","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","article-title":"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial","volume":"10","author":"Li","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.virol.2024.110026_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105688","article-title":"T4 bacteriophage nanoparticles engineered through CRISPR provide a versatile platform for rapid development of flu mucosal vaccines","volume":"217","author":"Li","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2024.110026_bib70","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.imlet.2019.10.013","article-title":"Mucosal vaccines: strategies and challenges","volume":"217","author":"Li","year":"2020","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.virol.2024.110026_bib71","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jmb.2007.05.008","article-title":"Assembly of the small outer capsid protein, Soc, on bacteriophage T4: a novel system for high density display of multiple large anthrax toxins and foreign proteins on phage capsid","volume":"370","author":"Li","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.virol.2024.110026_bib72","article-title":"The effects of secretory IgA in the mucosal immune system","volume":"2020","author":"Li","year":"2020","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.virol.2024.110026_bib73","unstructured":"Liew, F., et al., SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine 87, 104402.."},{"key":"10.1016\/j.virol.2024.110026_bib74","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/21645515.2015.1009345","article-title":"Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases","volume":"11","author":"Lin","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2024.110026_bib75","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib76","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1016\/j.vaccine.2008.03.037","article-title":"A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults","volume":"26","author":"Lyons","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2024.110026_bib77","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0065-3519(99)80043-3","article-title":"Vaccination of wildlife against rabies: successful use of a vectored vaccine obtained by recombinant technology","volume":"41","author":"Mackowiak","year":"1999","journal-title":"Adv. Vet. Med."},{"key":"10.1016\/j.virol.2024.110026_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104298","article-title":"Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: an open-label partially-randomised ascending dose phase I trial","volume":"85","author":"Madhavan","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.virol.2024.110026_bib79","first-page":"108","article-title":"Effect of human rotavirus vaccine on severe diarrhea in African infants","volume":"28","author":"Madhi","year":"2016","journal-title":"Malawi Med. J."},{"key":"10.1016\/j.virol.2024.110026_bib80","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13567-014-0077-8","article-title":"Twenty year experience of the oral rabies vaccine SAG2 in wildlife: a global review","volume":"45","author":"M\u00e4hl","year":"2014","journal-title":"Vet Res"},{"key":"10.1016\/j.virol.2024.110026_bib81","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13567-017-0459-9","article-title":"Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(\u00ae)): a global review","volume":"48","author":"Maki","year":"2017","journal-title":"Vet Res"},{"key":"10.1016\/j.virol.2024.110026_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/science.abo2523","article-title":"Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses","volume":"378","author":"Mao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.virol.2024.110026_bib83","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jama.2022.22759","article-title":"Urgent need for next-generation COVID-19 vaccines","volume":"329","author":"Marks","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.virol.2024.110026_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2020.112937","article-title":"Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples","volume":"489","author":"Mazzini","year":"2021","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.virol.2024.110026_bib85","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature10863","article-title":"Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine","volume":"483","author":"McDole","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110026_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001397","article-title":"Inside the mucosal immune system","volume":"10","author":"McGhee","year":"2012","journal-title":"PLoS Biol."},{"key":"10.1016\/j.virol.2024.110026_bib87","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/QAD.0000000000003414","article-title":"T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa","volume":"37","author":"McMahon","year":"2023","journal-title":"AIDS"},{"key":"10.1016\/j.virol.2024.110026_bib88","first-page":"165","article-title":"Chitosan-based nanoparticles in mucosal vaccine delivery","volume":"73","author":"Mehrabi","year":"2018","journal-title":"Arch Razi Inst"},{"key":"10.1016\/j.virol.2024.110026_bib89","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0140-6736(12)60921-0","article-title":"Polio vaccines and the eradication of poliomyelitis","volume":"380","author":"Minor","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2024.110026_bib90","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/cei.13285","article-title":"Mucosal vaccines and technology","volume":"196","author":"Miquel-Clop\u00e9s","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib91","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cell.2017.11.034","article-title":"Modulation of myelopoiesis progenitors is an integral component of trained immunity","volume":"172","author":"Mitroulis","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.virol.2024.110026_bib92","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/imcb.12505","article-title":"Vaccine-induced immune thrombosis and thrombocytopenia syndrome following adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a novel hypothesis regarding mechanisms and implications for future vaccine development","volume":"99","author":"Monagle","year":"2021","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.virol.2024.110026_bib93","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5455\/medarh.2015.69.236-239","article-title":"Diagnostic significance of reduced IgA in children","volume":"69","author":"Nurkic","year":"2015","journal-title":"Med. Arch."},{"key":"10.1016\/j.virol.2024.110026_bib94","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1128\/CMR.14.2.430-445.2001","article-title":"Vaccination strategies for mucosal immune responses","volume":"14","author":"Ogra","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.virol.2024.110026_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abj5129","article-title":"Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA","volume":"6","author":"Oh","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.virol.2024.110026_bib96","series-title":"Oral Vaccination of Dogs against Rabies: Guidance for Research on Oral Rabies Vaccines and Field Application of Oral Vaccination of Dogs against Rabies","author":"Organization","year":"2021"},{"key":"10.1016\/j.virol.2024.110026_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312776","article-title":"3D structures of IgA, IgM, and components","volume":"22","author":"Pan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.virol.2024.110026_bib98","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2217\/fmb-2017-0128","article-title":"Causes of impaired oral vaccine efficacy in developing countries","volume":"13","author":"Parker","year":"2018","journal-title":"Future Microbiol."},{"issue":"Suppl. 2","key":"10.1016\/j.virol.2024.110026_bib99","doi-asserted-by":"crossref","first-page":"S413","DOI":"10.1086\/520603","article-title":"Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice","volume":"196","author":"Patel","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110026_bib100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.4161\/hv.19568","article-title":"The mucosal vaccine quandary: intranasal vs. sublingual immunization against influenza","volume":"8","author":"Pedersen","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2024.110026_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104585","article-title":"Mucosal vaccines for SARS-CoV-2: triumph of hope over experience","volume":"92","author":"Pilapitiya","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.virol.2024.110026_bib102","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib103","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110026_bib104","doi-asserted-by":"crossref","first-page":"E1509","DOI":"10.1503\/cmaj.221320","volume":"194","author":"Pucchio","year":"2022","journal-title":"Polio. Cmaj"},{"key":"10.1016\/j.virol.2024.110026_bib105","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd8003","article-title":"Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-resident memory T cells","volume":"6","author":"Rakhra","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.virol.2024.110026_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.virol.2024.110026_bib107","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1093\/infdis\/174.Supplement_1.S107","article-title":"Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines","volume":"174","author":"Rennels","year":"1996","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110026_bib108","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1128\/JVI.02864-12","article-title":"Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates","volume":"87","author":"Richardson","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110026_bib109","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1517\/17425247.2014.931936","article-title":"Intranasal formulations: promising strategy to deliver vaccines","volume":"11","author":"Riese","year":"2014","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.virol.2024.110026_bib110","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/pathogens3020390","article-title":"Secretory IgA is concentrated in the outer layer of colonic mucus along with gut bacteria","volume":"3","author":"Rogier","year":"2014","journal-title":"Pathogens"},{"key":"10.1016\/j.virol.2024.110026_bib111","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa052434","article-title":"Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis","volume":"354","author":"Ruiz-Palacios","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110026_bib112","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40249-016-0173-2","article-title":"Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and meta-analysis","volume":"5","author":"Santos","year":"2016","journal-title":"Infect Dis Poverty"},{"key":"10.1016\/j.virol.2024.110026_bib113","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jconrel.2016.02.014","article-title":"Mucosal vaccine delivery: current state and a pediatric perspective","volume":"240","author":"Shakya","year":"2016","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"key":"10.1016\/j.virol.2024.110026_bib114","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41541-023-00717-8","article-title":"Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin(\u00ae))","volume":"8","author":"Singh","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.virol.2024.110026_bib115","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.immuni.2013.09.013","article-title":"Lung airway-surveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus","volume":"39","author":"Sl\u00fctter","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.virol.2024.110026_bib116","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb6852","article-title":"Tissue-resident CD4(+) T helper cells assist the development of protective respiratory B and CD8(+) T cell memory responses","volume":"6","author":"Son","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.virol.2024.110026_bib117","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.virol.2024.110026_bib118","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2017.03.013","article-title":"The evolutionary pathway to virulence of an RNA virus","volume":"169","author":"Stern","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.virol.2024.110026_bib119","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrmicro2384","article-title":"The role of secretory antibodies in infection immunity","volume":"8","author":"Strugnell","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.virol.2024.110026_bib120","volume":"vol. 118","author":"Sun","year":"2021"},{"key":"10.1016\/j.virol.2024.110026_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1063679","article-title":"Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)","volume":"13","author":"Sunagar","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib122","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb6808","article-title":"T resident helper cells promote humoral responses in the lung","volume":"6","author":"Swarnalekha","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.virol.2024.110026_bib123","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1073\/pnas.1300867110","article-title":"In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine","volume":"110","author":"Tao","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.virol.2024.110026_bib124","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s11095-010-0094-x","article-title":"Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles","volume":"27","author":"Thomas","year":"2010","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.virol.2024.110026_bib125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41541-022-00509-6","article-title":"Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2","volume":"7","author":"Tioni","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.virol.2024.110026_bib126","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/oxfordjournals.aje.a121306","article-title":"Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines","volume":"94","author":"Top","year":"1971","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.virol.2024.110026_bib127","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/infdis\/124.2.148","article-title":"Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans","volume":"124","author":"Top","year":"1971","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110026_bib128","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0264-410X(99)00334-5","article-title":"Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses","volume":"18","author":"Treanor","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2024.110026_bib129","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41385-020-0309-3","article-title":"Long-term maintenance of lung resident memory T cells is mediated by persistent antigen","volume":"14","author":"Uddb\u00e4ck","year":"2021","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib130","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1473-3099(22)00307-3","article-title":"Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2\/3 study","volume":"22","author":"Vadrevu","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2024.110026_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.781280","article-title":"An intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection","volume":"12","author":"van der Ley","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2024.110026_bib132","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/01.inf.0000220229.51531.47","article-title":"A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine","volume":"25","author":"Vesikari","year":"2006","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.virol.2024.110026_bib133","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(07)61744-9","article-title":"Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study","volume":"370","author":"Vesikari","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2024.110026_bib134","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa052664","article-title":"Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine","volume":"354","author":"Vesikari","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110026_bib135","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1084\/jem.20122465","article-title":"A role for gut-associated lymphoid tissue in shaping the human B cell repertoire","volume":"210","author":"Vossenk\u00e4mper","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.virol.2024.110026_bib136","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2024.110026_bib137","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2024.110026_bib138","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02180-19","article-title":"Generation of DelNS1 influenza viruses: a strategy for optimizing live attenuated influenza vaccines","volume":"10","author":"Wang","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.virol.2024.110026_bib139","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41392-023-01423-6","article-title":"Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.virol.2024.110026_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105765","article-title":"Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters","author":"Wang","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2024.110026_bib141","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","article-title":"Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.virol.2024.110026_bib142","volume":"vol. 118","author":"Wang","year":"2021"},{"key":"10.1016\/j.virol.2024.110026_bib143","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf1555","article-title":"Enhanced SARS-CoV-2 neutralization by dimeric IgA","volume":"13","author":"Wang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.virol.2024.110026_bib144","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf1555","article-title":"Enhanced SARS-CoV-2 neutralization by dimeric IgA","volume":"13","author":"Wang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.virol.2024.110026_bib145","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2015.01.001","article-title":"Intranasal immunization with an adenovirus vaccine protects Guinea pigs from Ebola virus transmission by infected animals","volume":"116","author":"Wong","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2024.110026_bib146","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2024.110026_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymeth.2006.05.016","article-title":"Pathogen recognition and development of particulate vaccines: does size matter?","volume":"40","author":"Xiang","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.virol.2024.110026_bib148","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.cell.2018.09.042","article-title":"Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity","volume":"175","author":"Yao","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.virol.2024.110026_bib149","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.chom.2020.04.003","article-title":"Engineering the live-attenuated polio vaccine to prevent reversion to virulence","volume":"27","author":"Yeh","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2024.110026_bib150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41586-023-06212-3","article-title":"Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3","volume":"619","author":"Yeh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110026_bib151","first-page":"463","article-title":"Innate immunity of the gut: mucosal defense in health and disease","volume":"38","author":"Yuan","year":"2004","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.virol.2024.110026_bib152","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12026-019-09107-6","article-title":"Combined prime-boost immunization with systemic and mucosal pneumococcal vaccines based on Pneumococcal surface protein A to enhance protection against lethal pneumococcal infections","volume":"67","author":"Zhang","year":"2019","journal-title":"Immunol. Res."},{"key":"10.1016\/j.virol.2024.110026_bib153","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2024.110026_bib154","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2024.110026_bib155","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S2213-2600(22)00131-X","article-title":"Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"10","author":"Zhu","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.virol.2024.110026_bib156","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh1547","article-title":"A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering","volume":"7","author":"Zhu","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.virol.2024.110026_bib157","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01822-22","article-title":"A bacteriophage-based, highly efficacious, needle- and adjuvant-free, mucosal COVID-19 vaccine","volume":"13","author":"Zhu","year":"2022","journal-title":"mBio"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224000473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224000473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:54:36Z","timestamp":1762221276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682224000473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":157,"alternative-id":["S0042682224000473"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2024.110026","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mucosal vaccines for viral diseases: Status and prospects","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2024.110026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110026"}}